Rheumatology

Classification criteria and recommendations for the diagnosis and clinical management of spondyloarthritis have been updated and were presented at EULAR 2026.

Researchers have highlighted, at EULAR 2026, different pathways through which the rheumatology patient’s experience can be enhanced.

Urate-lowering therapy in a treat-to-target strategy can foster higher remission rates in patients with gout, according to new data presented at EULAR 2026.

CAR-T cell therapies prove promising in treatment-refractory rheumatic and musculoskeletal diseases, according to new research presented at EULAR 2026.

A randomised trial has found that early DMARD therapy improves short-term disease activity in undifferentiated arthritis, though long-term outcomes remained similar.

A phase II trial found the MK2 inhibitor CC-99677 was well tolerated but failed to significantly improve ankylosing spondylitis symptoms.

Patients receiving vunakizumab for radiographic axial spondyloarthritis demonstrated improved clinical responses through 32 weeks, a new trial has shown.

Researchers reported significant dose-dependent improvements in lupus skin disease activity with the oral TLR7/8 inhibitor enpatoran.